The main goal of this trial is to identify the optimal cut-off score of a Scoring System to discriminate between mild chemotherapy-induced peripheral neuropathy (CIPN) and no CIPN in breast cancer survivors previously treated with taxane-based chemotherapy and adjuvant radiotherapy.
Histologically proven breast cancer
Previous treatment with taxane-based chemotherapy followed by adjuvant radiotherapy
Mild or no CIPN according to the Total Neuropathy Score
Female gender
Disease-related skin disorders of the lower extremities (e.g., related to skin infections, bullous dermatoses, dermatitis, papulo-squamous skin disorders, or urticaria/erythema)
Pregnancy, Lactation
Expected non-compliance